Abstract
Before the advent of levodopa therapy for Parkinson’s disease, surgical lesioning of the motor thalamus or globus pallidus represented the primary therapeutic intervention for Parkinson’s disease and essential tremor at a time when effective medical alternatives were severely limited. In this context, Irving S. Cooper directed one of the most prolific and controversial lesioning practices of the mid-20th century, performing thousands of procedures and documenting outcomes. Through chemopallidectomy, chemothalamectomy, and later cryosurgical techniques, Cooper investigated the relationship between basal ganglia targets and motor symptoms, establishing reproducible symptom-anatomy associations for tremor and rigidity.
Cooper’s work introduced a systematic approach to target selection that contrasted with earlier lesioning methods. His outcomes demonstrated alleviation of tremor and rigidity when lesions were accurately placed, while highlighting risks of bilateral procedures. Most notably, the cryogenic "test-freeze" method allowed reversible intraoperative physiological inhibition, enabling assessment of clinical benefit before permanent lesions.
Although many techniques were later abandoned, principles derived from Cooper’s work continue to shape contemporary practice. Modern neuromodulation strategies, including deep brain stimulation and MR-guided focused ultrasound, rely on symptom-based targeting paradigms established during the lesioning era. This vignette examines how Cooper’s innovations informed modern targeting strategies and standards of safety in functional neurosurgery.